Cubist Systematic Strategies LLC Takes $4.02 Million Position in Haleon plc (NYSE:HLN)

Cubist Systematic Strategies LLC acquired a new position in Haleon plc (NYSE:HLN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 421,631 shares of the company’s stock, valued at approximately $4,022,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HLN. Sierra Ocean LLC bought a new position in shares of Haleon in the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. bought a new position in Haleon in the fourth quarter valued at approximately $35,000. Spire Wealth Management acquired a new stake in Haleon during the 4th quarter worth $39,000. FIL Ltd raised its position in shares of Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after acquiring an additional 1,270 shares during the last quarter. Finally, Addison Advisors LLC lifted its stake in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after purchasing an additional 1,106 shares during the period. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HLN. HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective on the stock in a research note on Friday. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Barclays reissued an “overweight” rating on shares of Haleon in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Haleon Price Performance

NYSE HLN opened at $10.75 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 52-week low of $8.22 and a 52-week high of $10.85. The business has a 50 day simple moving average of $10.20 and a 200 day simple moving average of $9.84. The stock has a market cap of $48.50 billion, a price-to-earnings ratio of 31.62, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio is currently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.